Sunshine Biopharma
SBFM | NASDAQ
$2.55
-$0.15 (-5.56%)
At close: Nov 16, 2026, 3:59 PM ET
$2.55
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:53 PM ET
Sunshine Biopharma Company Profile
Company profile explainedCompany Profile
Sunshine Biopharma, Inc. operates as a pharmaceutical entity and a provider of nutritional supplements, primarily dedicating its efforts to the research and development of novel anticancer therapies. A key pipeline candidate is Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin, designed to combat a broad spectrum of malignancies, including leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, and liver cancers. Notably, Adva-27a also demonstrates efficacy against multidrug-resistant cancer cells, encompassing pancreatic, breast, small-cell lung, and uterine sarcoma cells. The company is also progressing SBFM-PL4, a compound under development as an anti-coronavirus treatment. In addition to its drug development, Sunshine Biopharma markets a range of nutritional products, such as the Essential 9 tablet and the Essential Calcium-Vitamin D supplement, alongside other scientifically formulated dietary aids. A collaboration with the University of Georgia supports the ongoing advancement of SBFM-PL4 as an anti-coronavirus agent. The firm's headquarters are situated in Pointe-Claire, Canada.
Key Executives
| Name | Position |
|---|---|
| Steve N. Slilaty | Chairman, President & Chief Executive Officer |
| Camille Sebaaly | CFO, Secretary & Director |
| Malek Chamoun | Chief Development Officer |
| Michel Roy | Chief Commercial Officer |
| Robert G. Ferreira | President of Sunshine Bio Investments Inc |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | DEF 14C | Filing |
| Oct 14, 2026 | PRE 14C | Filing |
| Oct 14, 2026 | 8-K | Current Report |
| Oct 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 13, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Oct 09, 2026 | 8-K | Current Report |
| Oct 09, 2026 | 424B4 | Filing |
| Oct 07, 2026 | EFFECT | Filing |
| Oct 05, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 02, 2026 | S-1 | Filing |
Sunshine Biopharma
| Country | United States |
| IPO Date | Feb 15, 2022 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 50 |
| CEO | Steve N. Slilaty |
Contact Details
333 Las Olas Way Fort Lauderdale,
Florida 33301 United States
Stock Details
| Ticker Symbol | SBFM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001402328 |
| CUSIP Number | 867781882 |
| ISIN Number | US8677818820 |
| SIC Code | 8731 |
Recent News
- 2 months ago / zacks.comSunshine Biopharma, Inc. (SBFM) Upgraded to Buy: Here's What You Should Know
Add to Watchlist
Select watchlists to add or remove SBFM